Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 281

1.

Amantadine as adjuvant therapy in the treatment of moderate to severe OCD: a double blind randomized trial with placebo control.

Naderi S, Faghih H, Aqamolaei A, Mortazavi SH, Mortezaei A, Sahebolzamani E, Rezaei F, Akhondzadeh S.

Psychiatry Clin Neurosci. 2018 Nov 28. doi: 10.1111/pcn.12803. [Epub ahead of print]

PMID:
30488617
2.

The effects of alcoholic extract of saffron (Crocus satious L.) on mild to moderate comorbid depression-anxiety, sleep quality, and life satisfaction in type 2 diabetes mellitus: A double-blind, randomized and placebo-controlled clinical trial.

Milajerdi A, Jazayeri S, Shirzadi E, Hashemzadeh N, Azizgol A, Djazayery A, Esmaillzadeh A, Akhondzadeh S.

Complement Ther Med. 2018 Dec;41:196-202. doi: 10.1016/j.ctim.2018.09.023. Epub 2018 Sep 26.

PMID:
30477839
3.

Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial.

Shakiba M, Moazen-Zadeh E, Noorbala AA, Jafarinia M, Divsalar P, Kashani L, Shahmansouri N, Tafakhori A, Bayat H, Akhondzadeh S.

Avicenna J Phytomed. 2018 Nov-Dec;8(6):513-523.

4.

Setting research priorities to achieve long-term health targets in Iran.

Mansoori P, Majdzadeh R, Abdi Z, Rudan I, Chan KY; Iranian CHNRI Health Research Priority Setting Group, Aarabi M, Ahmadnezhad E, Ahmadnia S, Akhondzadeh S, Azin A, Azizi F, Dehnavieh R, Eini-Zinab H, Farzadfar F, Farzaei MH, Ghanei M, Haghdoost A, Hantoushzadeh S, Heydari G, Joulaei H, Kalantari N, Kelishadi R, Khosravi A, Larijani B, Mahvi AH, Bavani ARM, Mesdaghinia A, Mokri A, Montazeri A, Mostafavi E, Motevalian SA, Naddafi K, Nikfar S, Nojoumi SA, Noroozian M, Olyaeemanesh A, Omidvar N, Ostadtaghizadeh A, Pourmalek F, Rahimi R, Rahimi-Movaghar A, Rashidian A, Razaghi E, Sadeghi-Bazargani H, Zalani GS, Soori H, Tabrizi JS, Vedadhir A, Yazdizadeh B, Yunesian M, Zare M.

J Glob Health. 2018 Dec;8(2):020702. doi: 10.7189/jogh.08.020702.

5.

Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice.

Roohi-Azizi M, Torkaman-Boutorabi A, Akhondzadeh S, Nejatisafa AA, Sadat-Shirazi MS, Zarrindast MR.

Physiol Behav. 2018 Oct 15;195:151-157. doi: 10.1016/j.physbeh.2018.08.002. Epub 2018 Aug 11.

PMID:
30107190
6.

Monoclonal Antibody for Reducing Memory and Learning Problems in Schizophrenia.

Akhondzadeh S.

Avicenna J Med Biotechnol. 2018 Jul-Sep;10(3):125. No abstract available.

7.

Iran's scientists uncrushed by decades of sanctions.

Akhondzadeh S.

Nature. 2018 Jul;559(7714):331. doi: 10.1038/d41586-018-05747-0. No abstract available.

PMID:
30022138
8.

Infectious agents and different course of multiple sclerosis: a systematic review.

Saberi A, Akhondzadeh S, Kazemi S.

Acta Neurol Belg. 2018 Jul 13. doi: 10.1007/s13760-018-0976-y. [Epub ahead of print] Review.

PMID:
30006858
9.

Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.

Ghajar A, Gholamian F, Tabatabei-Motlagh M, Afarideh M, Rezaei F, Ghazizadeh-Hashemi M, Akhondzadeh S.

Hum Psychopharmacol. 2018 Jul;33(4):e2662. doi: 10.1002/hup.2662. Epub 2018 Jun 14.

PMID:
29901250
10.

Opioid Use Disorder Induces Oxidative Stress and Inflammation: The Attenuating Effect of Methadone Maintenance Treatment.

Salarian A, Kadkhodaee M, Zahmatkesh M, Seifi B, Bakhshi E, Akhondzadeh S, Adeli S, Askari H, Arbabi M.

Iran J Psychiatry. 2018 Jan;13(1):46-54.

11.

Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Arabzadeh S, Zeinoddini A, Mostafavi SA, Hamedi M, Ehyaii A, Ghaleiha A, Zeinoddini A, Akhondzadeh S.

Iran J Psychiatry. 2018 Jan;13(1):1-9.

12.

Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial.

Khalaj M, Saghazadeh A, Shirazi E, Shalbafan MR, Alavi K, Shooshtari MH, Laksari FY, Hosseini M, Mohammadi MR, Akhondzadeh S.

J Psychiatr Res. 2018 Aug;103:104-111. doi: 10.1016/j.jpsychires.2018.04.022. Epub 2018 May 1.

PMID:
29807317
13.

Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial.

Keshavarz SA, Mostafavi SA, Akhondzadeh S, Mohammadi MR, Hosseini S, Eshraghian MR, Chamari M.

Clin Nutr ESPEN. 2018 Jun;25:37-43. doi: 10.1016/j.clnesp.2018.03.001. Epub 2018 Mar 17.

PMID:
29779816
14.

Is transcranial direct current stimulation an effective modality in reducing food craving? A systematic review and meta-analysis.

Mostafavi SA, Khaleghi A, Mohammadi MR, Akhondzadeh S.

Nutr Neurosci. 2018 May 7:1-13. doi: 10.1080/1028415X.2018.1470371. [Epub ahead of print]

PMID:
29734883
15.

Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial.

Arabzadeh S, Hakkikazazi E, Shahmansouri N, Tafakhori A, Ghajar A, Jafarinia M, Akhondzadeh S.

J Affect Disord. 2018 Aug 1;235:236-241. doi: 10.1016/j.jad.2018.02.056. Epub 2018 Feb 22.

PMID:
29660637
16.

The effect of saffron (Crocus sativus L.) hydroalcoholic extract on metabolic control in type 2 diabetes mellitus: A triple-blinded randomized clinical trial.

Milajerdi A, Jazayeri S, Hashemzadeh N, Shirzadi E, Derakhshan Z, Djazayeri A, Akhondzadeh S.

J Res Med Sci. 2018 Feb 20;23:16. doi: 10.4103/jrms.JRMS_286_17. eCollection 2018.

17.

Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.

Ghazizadeh-Hashemi M, Ghajar A, Shalbafan MR, Ghazizadeh-Hashemi F, Afarideh M, Malekpour F, Ghaleiha A, Ardebili ME, Akhondzadeh S.

J Affect Disord. 2018 May;232:127-133. doi: 10.1016/j.jad.2018.02.057. Epub 2018 Feb 21.

PMID:
29486338
18.

A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Zanjan, Iran.

Noorbala AA, Bagheri Yazdi SA, Faghihzadeh S, Kamali K, Faghihzadeh E, Hajebi A, Akhondzadeh S, Armani Kian A, Nasr S.

Arch Iran Med. 2017 Nov 1;20(11 Suppl. 1):S127-S130.

PMID:
29481147
19.

A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of Yazd, Iran.

Noorbala AA, Bagheri Yazdi SA, Faghihzadeh S, Kamali K, Faghihzadeh E, Hajebi A, Akhondzadeh S, Yasini Ardekani SM, Farahzadi MH, Zare F.

Arch Iran Med. 2017 Nov 1;20(11 Suppl. 1):S123-S126.

PMID:
29481146
20.

A Survey on Mental Health Status of Adult Population Aged 15 and above in the Province of West Azarbaijan, Iran.

Noorbala AA, Bagheri Yazdi SA, Faghihzadeh S, Kamali K, Faghihzadeh E, Hajebi A, Akhondzadeh S, Sedighnia A, Karimi H.

Arch Iran Med. 2017 Nov 1;20(11 Suppl. 1):S119-S122.

PMID:
29481145

Supplemental Content

Loading ...
Support Center